key: cord-0936905-o5euo2yq
authors: Jia, Zaixing; Gong, Wenping
title: Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
date: 2021-04-21
journal: J Korean Med Sci
DOI: 10.3346/jkms.2021.36.e124
sha: 765318e26342ee04428725277df9fd11b6f188c4
doc_id: 936905
cord_uid: o5euo2yq

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which has spread worldwide since it was first identified in Wuhan, China, at the end of 2019. With the global transmission of the virus, a large number of SARS-CoV-2 variants have also appeared, especially, emerging strains that have recently been discovered in the United Kingdom (variant 20I/501Y.V1, lineage B.1.1.7), South Africa (variant 20H/501Y.V2, lineage B.1.351), and Brazil (variant 20 J/501Y.V3, and lineage P.1). The common feature of these variants is that they share the N501Y mutation involving the SARS-CoV-2 spike (S) protein, which is precisely the target of most COVID-19 vaccines. Furthermore, mutations such as N501Y, E484K, and K417N in the S protein may affect viral fitness and transmissibility. However, current research on the impact of these variants on COVID-19 vaccines is still lacking. Herein, we briefly explain why most COVID-19 vaccines target the S protein, update the progress of research regarding S protein-related COVID-19 vaccines, review the latest studies concerning the effects of S protein variants on COVID-19 vaccines, and finally, propose certain strategies to deal with SARS-CoV-2 variants.

Although the EUA of vaccines has brought hope to people under threat of the COVID-19 pandemic, the emergence of SARS-CoV-2 variants at the end of 2020 has rendered the situation confusing. On December 19, 2020, the British government imposed a level 4 blockade on some parts of England due to the spread of the SARS-CoV-2 variant 20I/501Y. V1 (lineage B.1.1.7). 7 At the end of December, the SARS-CoV-2 variant 20H/501Y.V2 (lineage B.1.351) appeared in South Africa. 8 Therefore, people cannot help but ask: why is the S protein essential for vaccine design? Can emergent SARS-CoV-2 variants escape immunity induced by COVID-19 vaccines? How should COVID-19 vaccines cope with SARS-CoV-2 variants?

The S protein, the most crucial surface protein of SARS-CoV-2, is a large trimeric transmembrane glycoprotein with many glycosylation modifications that form a unique corolla structure on the surface of the virus. The S protein consists of the S1 and S2 subunits (Fig. 1) . The S1 subunit mainly contains the receptor-binding domain (RBD), which is responsible for recognizing receptors. Mutations involving RBD-associated amino acids lead to changes in the preference and infection characteristics of viral species. The S2 subunit comprises elements that are essential for membrane fusion. The S protein plays a vital role in the binding of the virus to, and its fusion with, the host cell membrane receptor. 10 Given its crucial role in SARS-CoV-2 infection and adaptive immunity, the S protein is an important target site for neutralizing antibodies and a key target for vaccine design. 

Since its discovery in Wuhan in 2019, SARS-CoV-2 has evolved into several co-circulating variants. In order to discuss these variants conveniently, they were divided into 12 major clades according to specific signature mutations, including 19A and 19B, which emerged in Wuhan, 20A, which arose from 19A and dominated the European outbreak in March 2020, 20B and 20C, which emerged in early 2020, and 20D to 20J, which emerged in the summer of 2020 ( Fig. 2A) . By analyzing the genomic epidemiology of SARS-CoV-2 obtained from nextstrain.org (https://nextstrain.org/ncov/global), we found that the viral mutations were more likely to occur in spring, autumn, and winter, and less likely in summer (as shown by white lines in Fig. 2A ). This may be related to the slow spread of the virus in summer due to higher temperatures, as demonstrated by a temporal multivariate time series model in a recent study. 11 In addition, we found that the number of mutants in the 20I/501Y.V1, 20H/501Y.V2, and 20J/501Y.V3 clades were higher than those in other clades (Fig. 2B) .

To determine mutations in SARS-CoV-2 gene sequences, we obtained, sequenced, and shared SARS-CoV-2 genomic data from the Nextstrain team (https://nextstrain.org/sarscov-2/) and GISAID Mutation Tracker (https://users.math.msu.edu/users/weig/SARS-CoV-2_ Mutation_Tracker.html). It was found that as many as 26,844 single mutations were tracked in 203,346 human coronavirus 2019 (hCoV-19) genomes, and the most frequent mutations were observed to involve the NSP3 and S proteins (Fig. 1) . Considering the importance of the S protein, we further focused on S protein mutations. By December 26, 2020, at least 5,003 mutations were identified in the S protein by Mutation Tracker (Supplementary Table 3 ). There were 13 nonsynonymous mutations with a total frequency of > 1,000, and three mutations that are of interest, including D614G, A222V, L18F, S477N, N439K, S98F, L5F, A262S, P272L, P681H, D1163Y, E583D, G1167V, Y453F, E484K, and N501Y (Fig. 1) . Among these mutations, five (L18F, S98F, A262S, A222V, and P272L) occurred in the N-terminal domain (NTD) of the S protein, and five (N439K, Y453F, S477N, E484K, and N501Y) appeared in the S protein RBD. 

A large number of previous studies and practices have demonstrated that viral mutations exist naturally, and these mutations rarely affect viral fitness or the effects of vaccines. However, the emergence of mutations in the spike protein of SARS-CoV-2 might impact viral fitness and transmissibility, particularly after the recent identification of three independent emerging strains in the UK (UK, 20I/501Y.V1), South Africa (20H/501Y.V2), and Brazil (20 J/501Y.V3). 12 The emergence of these variant strains is remarkable because the N501Y mutation shared by the three strains is located in the key RBD of the S protein. 13 This mutation may enhance the ability of SARS-CoV-2 to bind to human receptor angiotensinconverting enzyme 2 (ACE2), thus accelerating the spread of the COVID-19 pandemic. 7,14 A preprint study published in medRxiv showed that serum of convalescent COVID-19 patients and vaccinators could neutralize the N501Y variant, suggesting that current SARS-CoV-2 vaccines will protect against the 20B/501Y.V1 strain. 15 6 In addition, the D614G, S477N, and E484K mutants of the S protein are considered to pose a risk of immune escape or increased ACE2 binding by the virus, thereby affecting COVID-19 vaccine development and antibody treatment. 16 A previous study reported that the D614G mutation increases susceptibility of the virus to neutralization, and the D614G mutation is not expected to threaten current vaccine development. 17 However, in another study, the D614G mutation did not alter the binding of the spike protein to ACE2 or the neutralization sensitivity of pseudoviruses. The authors suggested that the D614G mutation might increase infectivity by assembling more functional S protein into virions. 18 S477N, a mutation involving the RBD, has emerged independently in Australia and is responsible for much of the summer 2020 outbreak. Previous studies have indicated that this mutation may slightly increase the ACE2 binding affinity 19 of the virus and confer resistance to multiple antibodies. 20 The E484K mutation is associated with the 501Y.V2 variant in South Africa and the 501Y.V3 variant identified in Manaus, Amazonas, and Brazil. 8, 12 Greaney et al. 21 found that E484K reduced the neutralizing potency of convalescent sera from some donors by 10fold. In one study, following the co-incubation of SARS-CoV-2 with convalescent plasma, the virus was reported to completely escape neutralization by day 73 due to the emergence of the E484 mutation. 22

On January 25, 2021, a preprint study in bioRxiv assessed the neutralizing capacity of sera from human subjects or non-human primates that received the mRNA-1273 vaccine and demonstrated that compared with vesicular stomatitis virus (VSV) pseudovirus, VSV pseudoviruses with S protein containing K417N-E484K-N501Y-D614G resulted in a 2.7-fold higher geometric mean titer reduction. 23 Another study evaluated antibody and memory B cell responses in a cohort of 20 volunteers vaccinated with the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines. The results showed that the neutralization activity induced by both vaccines decreased slightly, but nevertheless, significantly, against SARS-CoV-2 variants encoding E484K or N501Y, or the K417N-E484K-N501Y combination. 24 On January 26, 2021, a preprint study in bioRxiv reported that Covaxin, the COVID-19 vaccine developed by Bharat Biotech, effectively neutralized the UK variant of SARS-CoV-2, reducing the possibility of immune escape by the mutant virus. 25 Similarly, the neutralizing activity of antibodies induced by the ChAdOx1 nCoV-19 vaccine was 9-fold lower against the B. This evidence indicates that mutations in the S protein have the potential to affect the binding of antibodies to host receptors, leading to a change in the infectivity and transmission efficiency of the virus, and its immune escape from neutralization after vaccination. There is still a lack of studies involving larger sample sizes to assess the impact of these mutations on COVID-19 vaccines. These issues need to be further investigated experimentally and clinically in the future.

Taken together, although the studies mentioned above have involved preliminary explorations regarding the protective effects of the approved vaccines against SARS-CoV-2 variants from different perspectives, there is still a lack of in-depth studies and studies with extensive sample sizes. Because we know little about these newly emerging mutants, we are still passive and slow with regard to dealing with these potential emergencies. In the future, the following measures should be taken to meet the challenges associated with SARS-CoV-2 variants:

(1) The monoclonal antibodies employed in the clinic should be tested again against the new variants. As a COVID-19 therapeutic agent, S protein-specific neutralizing antibodies can interact with the SARS-CoV-2 S protein to inhibit the virus from invading the human body. Monoclonal antibodies have been authorized for emergency use. It has been reported that viral mutants may reduce the effectiveness of neutralizing antibodies. 29 Therefore, it is urgent to confirm the efficacy of these monoclonal and serum antibodies in neutralizing mutant viruses. Spike Protein Mutation is a Challenge for Vaccine Development people strictly abide by these public health control strategies, SARS-CoV-2 transmission would decrease, thereby lowering the frequency of mutations. In the face of the rapidly mutating virus, formulating and following public health control strategies is one of the most effective and economical strategies to deal with such crises. (6) Efforts should be made to curb the spread of variant SARS-CoV-2 strains through international cooperation and by strengthening immigration quarantine. Experience and studies indicate that the rapid spread of COVID-19 is closely related to intensive personnel exchanges and cross-border travel. 32 What is even more worrying is that variant SARS-CoV-2 viruses tend to have stronger transmission capabilities, which makes the spread of such variants more difficult to control internationally. To circumvent this challenge, effective international cooperation strategies should be formulated and implemented, and at the same time, countries should strengthen their immigration quarantine policies to reduce the risk of the cross-border transmission of SARS-CoV-2 variants.

In summary, mutations of SARS-CoV-2 have presented new challenges to the prevention and treatment of COVID-19. Most COVID-19 vaccines that have been approved for emergency use or are still in clinical research are designed based on the S protein. Unfortunately, the mutation frequency of the S protein is very high, and some mutations (such as E484K, N501Y, and K417N) affect the transmission and neutralization of the SARS-CoV-2 virus. Recently, there have been studies concerning SARS-CoV-2 mutants and EUA vaccines published online on preprint platforms; however, the results of these studies are inconsistent or even contradictory. Thus, surveillance activities, including gene sequencing and evaluation of vaccine effectiveness against SARS-CoV-2 variants, should be strengthened.

The Advisory Committee on Immunization Practices' interim recommendation for use of Moderna COVID-19 vaccine -United States

Covid-19: UK approves Moderna vaccine to be given as two doses 28 days apart

Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week

Covid-19: Russia approves vaccine without large scale testing or published results

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Immunogenicity of the Ad26.COV2.S vaccine for COVID-19

Emergence of SARS-CoV-2 B.1.1.7 lineage -United States

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens

Analysis of the spread of COVID-19 in the USA with a spatiotemporal multivariate time series model

Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the spike protein

GISAID. UK reports new variant

Modelling conformational state dynamics and its role on infection for SARS-CoV-2 Spike protein variants

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera

Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment

D614G spike mutation increases SARS CoV-2 susceptibility to neutralization

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Mutations strengthened SARS-CoV-2 infectivity

Evolution of antibody immunity to SARS-CoV-2

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. Forthcoming

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Neutralization of UKvariant VUI-202012/01 with COVAXIN vaccinated human serum. bioRxiv. Forthcoming

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease

Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Mice with humanized-lungs and immune system -an idealized model for COVID-19 and other respiratory illness

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

SARS-COV-2: transmission routes and environments

We would like to thank Editage (www.editage.cn) for English language editing. Supplementary Table 1